Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

gefurulimab

A humanized bispecific VHH antibody directed against terminal complement protein C5 and albumin, with potential anti-inflammatory and immunomodulatory activities. Upon administration, gefurulimab, with its anti-C5 antibody moiety, targets and binds to terminal complement protein C5, thereby blocking the terminal complement pathway of complement activation. This inhibits complement-mediated inflammation and cell lysis. Excessive complement activation plays a key role in various inflammatory and autoimmune diseases, and leads to tissue destruction. The binding of gefurulimab to albumin, with its albumin binding domain, increases its half-life.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Code name:	ALXN 1720 ALXN-1720 ALXN1720

gefurulimab

Search NCI's Drug Dictionary